In 2025, the sector in Europe recorded a value of USD 151.62 billion, equating to a year-over-year growth of 6.3%.
Current projections suggest that by 2033, the Europe Infusion Services Market valuation will total USD 353.93 billion, registering an estimated CAGR of 11.2% during the forecast period.
Universal healthcare coverage sustains high biologic infusion uptake, while cost-containment policies across member states are encouraging biosimilar substitution within hospital-based programs.
The European Medicines Agency continues biosimilar approvals, expanding competitive supply of infused biologics and influencing reimbursement pricing structures.
DataCube Research Report (Feb 2026): This analysis uses 2024 as the actual year, 2025 as the estimated year, and calculates CAGR for the 2025-2033 period.
*Research Methodology: This report is based on DataCube’s proprietary 3-stage forecasting model, combining primary research, secondary data triangulation, and expert validation.
[Learn more]